Alzheimer’s drug spurs some hope

For the first time, researchers are reporting that a treatment might help stabilize Alzheimer’s disease for as much as three years, although the evidence is weak and in only four patients. The drug is Gammagard, made by Baxter International Inc. Doctors say that four patients who have been receiving the highest dose for three years showed no decline on memory and cognition tests. A dozen others on different doses or shorter treatment times didn’t fare as well.

For the first time, researchers are reporting that a treatment might help stabilize Alzheimer’s disease for as much as three years, although the evidence is weak and in only four patients.

The drug is Gammagard, made by Baxter International Inc. Doctors say that four patients who have been receiving the highest dose for three years showed no decline on memory and cognition tests. A dozen others on different doses or shorter treatment times didn’t fare as well.

This study was far too small to prove the treatment works, but a more rigorous one involving 400 patients will give results within a year.

Still, the findings from the small study encouraged doctors at the Alzheimer’s Association International Conference in Vancouver, British Columbia, where they were presented on Tuesday.

“It’s tantalizing. If you were to pick out four people with Alzheimer’s disease, the likelihood that they would perform the same on standardized tests three years later is very, very tiny,” said William Thies, the association’s scientific director.

People typically go from diagnosis to death in about eight years, so to be stable for three years “is a long time,” he said. “We shouldn’t get euphoric and we shouldn’t get unreasonable enthusiasm, but this is a positive piece of data.”

The need for an effective treatment is huge: About 35 million people worldwide have dementia, and Alzheimer’s is the most common type. In the U.S., about five million have Alzheimer’s. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.

Gammagard is intravenous immune globulin, or IVIG — multiple, natural antibodies culled from donated blood. Half a dozen companies already sell IVIG to treat immune system and blood disorders. These antibodies may help remove amyloid, the sticky plaque that clogs patients’ brains, sapping memory and ability to think.

On Tuesday, Dr. Norman Relkin, head of a memory disorders program at New York-Presbyterian Hospital/Weill Cornell Medical Center, gave three-year follow-up results on 16 of 24 patients in an earlier study of Gammagard aimed at finding the right dose to use in the larger study. The other eight are no longer being followed, and at least some of them have died.

After the early study ended, some participants were kept on Gammagard and some who had been receiving dummy infusions were switched to Gammagard.

Relkin found:

l As a group, the 11 patients started on various doses of Gammagard fared better than the five started on dummy infusions.

l The five given dummy treatments declined more slowly after they were switched to Gammagard.

l All four participants originally given the highest dose and kept on that dose for three years showed no decline in cognition.

“To have all four not progress was very eye-opening,” Relkin said. Even a single patient who doesn’t decline over three years is unusual, he said.

“When I see that in clinical practice, I start to question whether the person has Alzheimer’s disease,” but all of these study participants were verified by advanced testing to have it, he said.

Jason Marder is among them. The New York City man, who turned 70 last week, was diagnosed with Alzheimer’s more than eight years ago and continues to get Gammagard infusions every two weeks from a visiting nurse at home. “I feel that I haven’t gone down, and that’s good,” he said in a recent interview. “I feel good. I’m very independent.”

His wife, Karin Marder, said: “He has slowed down, no question about it. His walk is a little slower but that could also have a lot to do with age. He’s still the Jason that I married. He’s still there. We still have a wonderful relationship together. I’m grateful for every day that he’s independent.”

Other doctors warned against over-optimism on these early results. Many previous drugs looked good until tested in large, definitive studies.

“That’s the only way we can get data we can really rely on,” said Dr. Reisa Sperling, a neurologist at Harvard-affiliated Brigham and Women’s Hospital in Boston.

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Alberta legislature to resume with throne speech, tabling of blockade bill

EDMONTON — Alberta politicians are returning to the legislature with a promise… Continue reading

Drugmaker readies possible coronavirus vaccine for testing

Drugmaker Moderna has shipped its first batch of a possible coronavirus vaccine… Continue reading

Scotiabank reports $2.3B first-quarter profit, tops expectations by analysts

TORONTO — Bank of Nova Scotia is optimistic its international ventures are… Continue reading

A look at carbon prices across the country

OTTAWA — As of Jan. 1, every Canadian and all Canadian businesses… Continue reading

More Red Deer seniors could be dealing with homelessness, inadequate housing in future

Red Deer is short 200 affordable seniors’ housing units: Bridges study shows

Your community calendar

Feb. 19 A Liberation of Holland event is being held at the… Continue reading

Barrier repairs will impact QE11 Highway traffic

Weather permitting, crews will carry out cable barrier repairs on the QEII… Continue reading

People don’t want to be governed

Not so long ago, Canada was caught up in a conversation about… Continue reading

Kids under 12 banned from heading soccer balls in practice

LONDON — Children up to the age of 12 will be banned… Continue reading

Oilers among winners, Panthers losers at NHL trade deadline

Mired in a run of one playoff appearance in 13 seasons, the… Continue reading

‘Mixed verdict’ in Weinstein case may disappoint some #MeToo supporters: scholar

The verdict in Harvey Weinstein’s sexual assault trial is in, but Canadian… Continue reading

Ex-coach gets 6 months in college scam, runs from courthouse

BOSTON — The former men’s tennis coach at the University of Texas… Continue reading

Kenney says investor confidence needed after Teck mine project killed

EDMONTON — Alberta Premier Jason Kenney says his government is taking action… Continue reading

Most Read